Fennec Pharmaceuticals presents new PEDMARK research at 2026 ASCO meeting
Fennec announced four independent studies evaluating PEDMARK (sodium thiosulfate) across multiple patient populations at ASCO 2026, expanding evidence for broader use beyond pediatric patients. The research demonstrates potential to reduce cisplatin-induced hearing loss in adolescent, young adult, and adult cancer patients, addressing a significant survivorship concern.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day